These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 19169608)

  • 21. Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
    Radaideh SM; Sledge GW
    Breast Cancer Res Treat; 2008 Sep; 111(2):203-8. PubMed ID: 17990102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes.
    Rivera E
    Am J Clin Oncol; 2010 Apr; 33(2):176-85. PubMed ID: 19675449
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials.
    Cuppone F; Bria E; Carlini P; Milella M; Felici A; Sperduti I; Nisticò C; Terzoli E; Cognetti F; Giannarelli D
    Cancer; 2008 Jul; 113(2):238-46. PubMed ID: 18470908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: a meta-analysis of phase III randomized control trials.
    Shao N; Wang S; Yao C; Xu X; Zhang Y; Zhang Y; Lin Y
    Breast; 2012 Jun; 21(3):389-93. PubMed ID: 22542064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [New combination chemotherapy regimens in the primary treatment of operable breast cancer].
    Conti F; Sergi D; Foggi P; Abbate MI; Lopez M
    Clin Ter; 2007; 158(1):55-75. PubMed ID: 17405660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations.
    Sparano JA
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):66-71. PubMed ID: 9768827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant use of taxanes for patients with breast cancer: we see the tip of the iceberg.
    Hudis C
    Clin Breast Cancer; 2002 Dec; 3(5):326-32. PubMed ID: 12533262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The best use of adjuvant chemotherapy: new drugs and new use of "old" drugs.
    Hudis C
    Breast; 2005 Dec; 14(6):570-5. PubMed ID: 16183287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Dose density and dose intensity in the treatment of breast cancer].
    Saintigny P; Assouad S; Gligorov J; Selle F; Roché H; Breau JL; Morère JF; Lotz JP
    Bull Cancer; 2004 Dec; 91 Suppl 4():S244-53. PubMed ID: 15899616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer.
    Eniu A; Palmieri FM; Perez EA
    Oncologist; 2005 Oct; 10(9):665-85. PubMed ID: 16249346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis.
    Petrelli F; Borgonovo K; Cabiddu M; Lonati V; Barni S
    Breast Cancer Res Treat; 2012 Sep; 135(2):335-46. PubMed ID: 22689092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma.
    Bria E; Giannarelli D; Felici A; Peters WP; Nisticò C; Vanni B; Cuppone F; Cognetti F; Terzoli E
    Cancer; 2005 Feb; 103(4):672-9. PubMed ID: 15637696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg.
    Dang C; Hudis C
    Clin Breast Cancer; 2006 Apr; 7(1):51-8. PubMed ID: 16764744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes.
    Tanabe M; Ito Y; Tokudome N; Sugihara T; Miura H; Takahashi S; Seto Y; Iwase T; Hatake K
    Breast Cancer; 2009; 16(4):301-6. PubMed ID: 19205831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant chemotherapy in 2005: standards and beyond.
    Piccart MJ; de Valeriola D; Dal Lago L; de Azambuja E; Demonty G; Lebrun F; Bernard-Marty Ch; Colozza M; Cufer T
    Breast; 2005 Dec; 14(6):439-45. PubMed ID: 16188441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Continued value of adjuvant anthracyclines as treatment for early breast cancer.
    Turner N; Biganzoli L; Di Leo A
    Lancet Oncol; 2015 Jul; 16(7):e362-9. PubMed ID: 26149888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Optimal role of docetaxel in adjuvant chemotherapy for early stage HER2-negative breast cancer].
    Fattoruso SI; Rossi S; Vici P; Di Filippo F; Botti C; Di Lauro L; Foggi P; Saracca E; Ferranti FR; Visca P; Lopez M
    Clin Ter; 2008; 159(6):443-7. PubMed ID: 19169606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strategies to decrease taxanes toxicities in the adjuvant treatment of early breast cancer.
    Tang SC
    Cancer Invest; 2009 Feb; 27(2):206-14. PubMed ID: 19235594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant anthracycline-based chemotherapy for early breast cancer: do the dose and schedule matter?
    Mano MS; Awada A; Kerr J; Canney P
    Cancer Treat Rev; 2005 Apr; 31(2):69-78. PubMed ID: 15847977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical trial design in metastatic breast cancer: a commentary.
    Levine M
    Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.